BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32744526)

  • 1. Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.
    Lambert LJ; Romero C; Sheffler DJ; Celeridad M; Cosford NDP; Tautz L
    J Vis Exp; 2020 Jul; (161):. PubMed ID: 32744526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
    Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
    J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
    Song Y; Zhao M; Zhang H; Yu B
    Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of SHP2 as an approach to block RAS-driven cancers.
    Chou YT; Bivona TG
    Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
    Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
    Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
    Yuan X; Bu H; Zhou J; Yang CY; Zhang H
    J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
    Liu W; Yu B; Xu G; Xu WR; Loh ML; Tang LD; Qu CK
    J Med Chem; 2013 Sep; 56(18):7212-21. PubMed ID: 23957426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
    Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
    Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
    Wu X; Xu G; Li X; Xu W; Li Q; Liu W; Kirby KA; Loh ML; Li J; Sarafianos SG; Qu CK
    J Med Chem; 2019 Feb; 62(3):1125-1137. PubMed ID: 30457860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
    Agazie YM; Movilla N; Ischenko I; Hayman MJ
    Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
    Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
    J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Biological Function of SHP2 in Human Disease].
    Li SM
    Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.